Rutgers University College

IR-MED Appoints Richard Serbin, Esq. to its Advisory Board

Retrieved on: 
Wednesday, September 13, 2023

He held senior management roles at Johnson & Johnson and served on the Board of Directors of numerous Johnson & Johnson subsidiary companies including Ethicon, Ortho, Johnson & Johnson Consumer Products, Pittman-Moore, McNeil and Johnson & Johnson Development Corporation, that company’s strategic venture capital division.

Key Points: 
  • He held senior management roles at Johnson & Johnson and served on the Board of Directors of numerous Johnson & Johnson subsidiary companies including Ethicon, Ortho, Johnson & Johnson Consumer Products, Pittman-Moore, McNeil and Johnson & Johnson Development Corporation, that company’s strategic venture capital division.
  • He formerly served as Chief Operating Officer of the Gorlin Companies and he served as President of Bradley Pharmaceuticals.
  • degree from Seton Hall Law School, and a Master’s Degree in Trade Regulations and Law from New York University Law School.
  • I’m pleased to join the company’s Advisory Board and contribute to its momentum toward bringing innovative, cost-effective, noninvasive solutions to market.”
    “We welcome Richard to our Advisory Board.

Seagen Names David R. Epstein as Chief Executive Officer and Director

Retrieved on: 
Thursday, November 10, 2022

Seagen Inc. (Nasdaq: SGEN) today announced that its Board of Directors has appointed David R. Epstein as Chief Executive Officer (CEO) and a member of the Board of Directors.

Key Points: 
  • Seagen Inc. (Nasdaq: SGEN) today announced that its Board of Directors has appointed David R. Epstein as Chief Executive Officer (CEO) and a member of the Board of Directors.
  • In addition, Seagen announced that Roger Dansey, M.D., who has served as Seagens Chief Medical Officer (CMO) since 2018 and as Interim CEO since May 2022, has been appointed President, Research and Development.
  • Mr. Epstein said, I have long admired Seagen as a leader in the development and commercialization of transformative cancer therapies.
  • David R. Epstein has more than 30 years of drug development, deal making, commercialization and people leadership experience on a global scale.

Comstock Announces New Director Nominations for 2022

Retrieved on: 
Thursday, April 7, 2022

She restructured and led Fiat-Chryslers fuel economy, greenhouse gas plan where she was the director of propulsion strategy.

Key Points: 
  • She restructured and led Fiat-Chryslers fuel economy, greenhouse gas plan where she was the director of propulsion strategy.
  • She was also an Executive Director at Ernst & Young, leading their future of mobility practice and brings Comstock over 30 years of leadership in innovation, electrification, mobility, and engineering.
  • We have transformed Comstock into a renewable energy company, enabling systemic decarbonization through our Cellulosic Fuels (Comstock Fuels) and Electrification Products (LiNiCo) businesses.
  • The Companys 2022 AGM has been scheduled for Thursday, May 26, 2022, at 9:00 a.m. PDT in Reno, Nevada, at the Atlantis Hotel.

Ring Therapeutics Announces the Appointment of Industry Leaders to its Board of Directors

Retrieved on: 
Thursday, March 17, 2022

All have exceptional proven track records of pioneering in the biotech and pharmaceutical industries and bring a wealth of expertise and experience to Ring.

Key Points: 
  • All have exceptional proven track records of pioneering in the biotech and pharmaceutical industries and bring a wealth of expertise and experience to Ring.
  • Dr. Nader joins Rings Board with extensive experience in the biotech industry and currently serves as chairman of Talaris Therapeutics, Benevolent AI and Neurvati Biosciences, as board director of Moderna, and as senior advisor of Blackstone Life Sciences.
  • Mr. Epstein brings more than 25 years of extensive drug development, leadership, and commercialization experience to Rings Board of Directors.
  • Ring Therapeutics is revolutionizing the programmable medicine space by harnessing the most abundant and diverse member of the human commensal virome, anelloviruses.